Singapore scientists have identified and named a new species of bacteria, Staphylococcus singaporensis sp.nov, named after Singapore. This newly-described pathogen is part of the Staphylococcus aureus (S. aureus) complex. S. aureus is a common bacterial cause of infections. Infections range from skin and wound infections, surgical infections, to blood stream infections which may be fatal.
Singapore scientists including Dr Raghav Sundar, Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), have created an intricate atlas of gastric cancer cells to offer more insight into how they can spread within the body.
A team of NUHS clinicians-scientists led by Prof Paul Chew, Department of Ophthalmology at NUS Medicine and Senior Consultant at NUH, has developed a glaucoma implant that helps to reduce patients’ eye pressure for a longer period of time, enabling less reliance on eye drops.
The National University Health System (NUHS) has embarked on a research and development programme within the academic healthcare cluster to explore the use of MR technology in clinical care. As part of the first phase of the research programme, a team of neurosurgeons at NUH has initiated a study to assess the feasibility of using holographic technology to spatially locate brain tumours when operating on patients.
Clinician-scientists from NUHS awarded $4.9 million grant to further develop the mitral valve bioprosthesis, named SingValve, which mimics the exact appearance, form and physical properties of a human mitral valve.
Adults with severe obesity who undergo metabolic-bariatric surgery (MBS) to lose weight, may have substantially lower mortality rates and longer life expectancy compared to those who tried to lose weight through conventional obesity management. The study findings by a team of clinicians and researchers from the National University Hospital (NUH), NUS Saw Swee Hock School of Public Health (SSHSPH) and NUS Yong Loo Lin School of Medicine (NUS Medicine) are published in the prestigious medical journal The Lancet in May.
Two widely-used therapies – oral hydroxychloroquine and povidone-iodine throat spray – have been found to significantly reduce the risk of COVID-19 infection, according to a study by a team of NUHS clinician-scientists.
A widely available cancer drug could potentially be used to treat COVID-19, found researchers from the National University Cancer Institute, Singapore - NCIS and the Icahn School of Medicine at Mount Sinai in the United States. The team found in pre-clinical trials that the drug, Topotecan, reduces the severity and death rate of SARS-CoV-2 infection by inhibiting the expression of inflammatory genes in lung models. This could have potential implications for COVID-19 treatment in humans, said NCIS.
A novel drug delivery technique that could extend the lifespans of advanced cancer patients has been successfully introduced in Singapore, at the National University Hospital - NUH and National University Cancer Institute, Singapore - NCIS — and for the first time in Asia. Known as pressurised intraperitoneal aerosol chemotherapy (PIPAC), the procedure targets cancers within the peritoneal cavity in the abdomen, including colon, gastric, and ovarian cancer.
After 8 years of discovery research, product development and clinical validation involving 5,248 subjects from Singapore and South Korea, NUHS has developed a non-invasive blood-based test targeting gastric cancer, more accurate than any of the existing conventional blood-based biomarker tests for detecting the cancer. This is a major event in the advancement of gastric cancer care, with the feasibility of rolling out the test in primary care in the near future.